Home » Press Releases

Press Releases

Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia

  • by

Initial pre-purchase of 10 million doses of oral vaccines with a potential deal for further orders worth hundreds of millions of dollars Prospective patient population of approximately 660 million throughout the Association of Southeast Asian Nations NEW YORK, Dec. 29, 2021 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP)… Read More »Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa

  • by

Oravax’s oral vaccine targets three surface proteins, making it potentially more effective against current and future variants Oravax’s oral vaccine should offer critical advantages, including logistics, distribution and delivery in less vaccinated regions, including Africa NEW YORK, Dec. 14, 2021 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com),… Read More »Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa

Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

  • by

– Millions of people in the region could benefit from the COVID-19 vaccine candidate- faster, easier, without the cold chain: The Oravax Oral Vaccine – The new partnership builds on the respective strengths of Oravax Medical and Genomma Lab to create compelling value for both companies and their… Read More »Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

Oramed Announces Oravax’s Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial

  • by

NEW YORK, October 29, 2021 – Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its majority-owned subsidiary, Oravax Medical Inc. (www.ora-vax.com), has received clearance from the South African Health Products Regulatory Authority to commence… Read More »Oramed Announces Oravax’s Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial

Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial

  • by

Oravax’s virus-like particle (VLP) vaccine being tested against COVID-19 variants including Delta  Oravax signs licensing deal for VLP injectable vaccine technology with Premas Biotech for commercialization in India  NEW YORK, July 21, 2021 – Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development… Read More »Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial

Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines

  • by

The Oral Vaccine Successfully Produced Antibodies in a Preclinical Study After a Single Dose Good candidate for protection against COVID variants due to triple antigen targeting Implications for potential ease of widescale distribution and administration anytime, anywhere for oral COVID-19 vaccine Efficacy following a single oral dose administration… Read More »Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines